Liver/Biliary Disorders

Top Story

Gilead Sciences receives CHMP positive opinion for DAA Vosevi

June 23, 2017

Gilead Sciences announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company’s Marketing Authorization Application for its direct-acting antiviral regimen sofosbuvir-velpatasvir-voxilaprevir, or Vosevi, according to a press release.

The application for Vosevi includes data from four phase 3 studies that support its safe use in patients with hepatitis C genotypes 1 through 6, with or without compensated cirrhosis, regardless of prior therapy. The recommended regimens are 8 weeks of treatment in DAA-naive patients and 12 weeks for those who have previously failed DAA therapy.

In the Journals

Interferon-based SVR in HCV reduced risk for extrahepatic manifestations

June 23, 2017
Sustained virologic response following interferon-based antiviral therapy in patients with hepatitis C reduced the risk for extrahepatic manifestations, according to…

No science needed to blame vaccines for illness, EU court rules

June 22, 2017
The European Union Court of Justice has ruled that illnesses can be attributed to vaccines during litigation without scientific proof. The judges decided that factors
In the Journals

Extensive preop chemo for colorectal liver metastases linked to hepatic atrophy

June 22, 2017
Results of a recently published study showed an association between extensive preoperative chemotherapy in patients with colorectal liver metastases and hepatic atrophy…
CME

HCV Updates and Case Challenges for the Rapidly Changing Landscape

This activity is supported by an educational grant from Merck & Co., Inc.

In the past few years, significant progress has been made in the treatment of chronic hepatitis C virus (HCV). Highly…
More »
GI Bookshelf

Question 47: What Is The Best Approach To The Patient With Suspected Sphincter Of Oddi Dysfunction?

From Curbside Consultation of the Pancreas: 49 Clinical Questions
More »
Featured
Digestive Disease Week

Digestive Disease Week

Video
Meeting News

VIDEO: Telemedicine aids treatment of patients with HCV, substance use disorders

April 23, 2017
More »

Gilead Sciences receives CHMP positive opinion for DAA Vosevi

June 23, 2017
Gilead Sciences announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company’s Marketing…

In the Journals

Interferon-based SVR in HCV reduced risk for extrahepatic manifestations

June 23, 2017
Sustained virologic response following interferon-based antiviral therapy in patients with hepatitis C reduced the risk for extrahepatic…

No science needed to blame vaccines for illness, EU court rules

June 22, 2017
The European Union Court of Justice has ruled that illnesses can be attributed to vaccines during litigation without scientific proof. The

In the Journals

Extensive preop chemo for colorectal liver metastases linked to hepatic atrophy

June 22, 2017
Results of a recently published study showed an association between extensive preoperative chemotherapy in patients with colorectal liver metastases…

In the Journals

Visceral obesity raises risk for NASH in lean, obese patients with NAFLD

June 21, 2017
In a comparative study of overweight-to-obese patients vs. lean patients with nonalcoholic fatty liver disease, researchers found an association…

In the Journals

Genetics outweigh abstinence in alcoholic hepatitis survival

June 20, 2017
Patients with severe alcoholic hepatitis who were homozygous for the rs738409:G variant in the PNPLA3 gene have an increased risk for mortality even…

In the Journals

MELD score determines DAAs’ cost-effectiveness pre- or post-transplant

June 20, 2017
Direct-acting antiviral treatment in patients with hepatitis C and cirrhosis was most cost-effective and cost-saving pre-liver transplant among those…

In the Journals

First-degree relatives of patients with NAFLD-cirrhosis at risk for advanced fibrosis

June 19, 2017
First-degree relatives of patients with nonalcoholic fatty liver disease and cirrhosis have a 12-times higher risk for developing advanced fibrosis…

In the Journals

Lack of treatment in HBV leads to increased FIB-4 no matter viral load

June 19, 2017
While patients with hepatitis B who received treatment had a significant initial decline in viral load and little to no change in FIB-4 score…

Editorial

Sifting Through and Taking Guidelines with a Grain of Salt

Healio Gastroenterology, June 2017
Nancy S. Reau, MD, FAASLD, AGAF
At the recent International Liver Congress, the European Association for the Study of the Liver released five different guidelines for the management…

More Headlines »
Advertisement
Advertisement